HOME > Publications

Publications

2022

Publication (International Journal)
  1. Tomita N, Morino E, Terada-Hirashima J, Uemura Y, Shimizu Y, Saito S, Suzuki T, Okumura N, Iwasaki H, Ebihara H, Shimojima M, Sugiura W, Ohmagari N,Ujiie M.
    Evaluating the Immunogenicity and Safety of a Smallpox Vaccine to Monkeypox in Healthy Japanese Adults: A Single-Arm Study.
    Life (Basel, Switzerland). 13(3):787,2023.
  2. Moriyama Y, Ujiie M. Monkeypox.
    N Engl J Med.388(7):671,2023.
  3. Matsuoka O, Ujiie M, Kikuchi H, Otake S, Chansinghakul D, Inoue T, Varghese K,Sirisuphmitr N, Hashiguchi T, Zambrano B, Nakama T, Frago C, Jordanov E, Dhingra MS.
    Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants Across a Broad Age Range (2-55 years) in Japan: A Phase III Randomized Study.
    Jpn J Infect Dis.76(3):174-182.2023
  4. Inada M, Saito S, Tsuzuki S, Okumura N, Sato L, Kamegai K, Sanada M, Komatsubara M, Shimojima M, Ebihara H, Kasuya F, Nagashima M, Sadamasu K, Yamamoto K, Ujiie M, Morioka S, Ohmagari N.
    Treatment with tecovirimat of the first two cases of monkeypox in Japan.
    J Infect Chemother. 29(4):418-421,2023
  5. Ujiie M, Kitano T, Tsuzuki S.
    Changing trends in HPV vaccination in Japan.
    Hum Vaccin Immunother.18(1):1-3,2022
  6. Ujiie M.
    Resumption of active recommendation of the human papillomavirus vaccine in Japan and future challenges for the National Immunization Program.
    Hum Vaccin Immunother. 18(6):2090777,2022
  7. Takeuchi JS, Fukunaga A, Yamamoto S, Tanaka A, Matsuda K, Kimura M, Kamikawa A, Kito Y, Maeda K, Ueda G, Mizoue T, Ujiie M, Mitsuya H, Ohmagari N, SugiuraW.
    SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study.
    Sci Rep. 12(1):15447,2022
  8. Okumura N, Tsuzuki S, Saito S, Hattori S, Takeuchi JS, Saito T, Ujiie M, Hojo H, Iwamoto N, Sugiura W, Mitsuya H, Ohmagari N.
    Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
    J Infect Chemother. 28(9):1340-1343,2023
  9. Suzuki T, Iwamoto N, Tsuzuki S, Kakumoto Y, Suzuki M, Ashida S, Oshiro Y, Nemoto T, Kanda K, Okuhama A, Yamada G, Inada M, Sato L, Miyazato Y, Akiyama Y, Saito S, Morioka S, Ujiie M, Hayakawa K, Sugiyama M, Mizokami M, Kodama EN, Ohmagari N.
    Interferon lambda 3 in the early phase of coronavirus disease-19 can predict oxygen requirement.
    Eur J Clin Invest. 52(9):e13808,2022.
  10. Maruki T, Iwamoto N, Kanda K, Okumura N, Yamada G, Ishikane M, Ujiie M, Saito M, Fujimoto T, Kageyama T, Saito T, Saito S, Suzuki T, Ohmagari N.
    Two cases of breakthrough SARS-CoV-2 infections caused by the Omicron variant (B.1.1.529 lineage) in international travelers to Japan.
    Clin Infect Dis. 75(1):e354-e356,2022
  11. Terayama Y, Tomita N, Terada-Hirashima J, Uemura Y, Shimizu Y, Takeuchi JS, Takamatsu Y, Maeda K, Mikami A, Ujiie M, Sugiura W.
    Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA).
    Life (Basel). 12(7):966,2022.
  12. Inada M, Ishikane M, Terada M, Matsunaga A, Maeda K, Iwamoto N, Ujiie M, Kutsuna S, Morioka S, Ishizaka Y, Mitsuya H, Ohmagari N.
    Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection.
    Int J Infect Dis. 119:18-20,2022.
  13. Miyazato Y, Terada M, Ujiie M, Saito S, Moriya A, Ando M, Ohmagari N.
    A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan.
    J Travel Med. 30(2):taac070,2022.
  14. Takahashi K, Ishikane M, Ujiie M, Iwamoto N, Okumura N, Sato T, Nagashima M, Moriya A, Suzuki M, Hojo M, Kanno T, Saito S, Miyamoto S, Ainai A, Tobiume M, Arashiro T, Fujimoto T, Saito T, Yamato M, Suzuki T, Ohmagari N.
    Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees.
    Emerg Infect Dis. 28(5):998-1001,2022.
  15. Ujiie M.
    Establishment of an emergency regulatory approval system in Japan in response to the COVID-19 pandemic and challenges in developing domestically produced vaccines.
    Glob Health Med. (30)4:144-145,2022.
  16. Khor SS, Omae Y, Takeuchi JS, Fukunaga A, Yamamoto S, Tanaka A, Matsuda K, Kimura M, Maeda K, Ueda G, Mizoue T, Ujiie M, Mitsuya H, Ohmagari N, Sugiura W, Tokunaga K.
    An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.
    Vaccines. 10(4):563,2022.
  17. Kamegai K, Hayakawa K,
    Towards the light at the end of the tunnel: Changes in clinical settings and political measures regarding COVID-19 from 2021, and future perspectives in Japan.
    Glob Health Med. 4(6):327-331,2022.
  18. Tomidokoro D, Asai Y, Hayakawa K, Kutsuna S, Terada M, Sugiura W, Ohmagari N, Hiroi Y,
    Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities.
    J Infect Chemother. 29(3):302-308,2023.
  19. Miyazato Y, Iwamoto N, Usui M, Sato T, Miyoshi-Akiyama T, Nagashima M, Mezaki K, Hayakawa K, Ohmagari N,
    Chromosomal coharboring of blaIMP-60 and mcr-9 in Enterobacter asburiae isolated from a Japanese woman with empyema: a case report.
    BMC Infect Dis. 22(1):762,2022.
  20. Kobayashi K, Kimura A, Sasaki R, Hayakawa K, Ohmagari N, Sugiura Y, Sugiyama H, Kokudo N,
    Actual situation of handling Tokyo 2020 Games-related patients at a designated hospital during COVID-19 pandemic.
    Glob Health Med. 4(4):230-232,2022.
  21. Nagata N, Nishijima S, Miyoshi-Akiyama T, Kojima Y, Kimura M, Aoki R, Ohsugi M, Ueki K, Miki K, Iwata E, Hayakawa K, Ohmagari N, Oka S, Mizokami M, Itoi T, Kawai T, Uemura N, Hattori M,
    Population-level Metagenomics Uncovers Distinct Effects of Multiple Medications on the Human Gut Microbiome.
    Gastroenterology. 163(4):1038-1052,2022.
  22. Suzuki M, Hayakawa K, Asai Y, Matsunaga N, Terada M, Ohtsu H, Toyoda A, Takasaki J, Hojo M, Yanagawa Y, Saito S, Yamamoto K, Ide S, Akiyama Y, Suzuki T, Moriya A, Mezaki K, Ohmagari N,
    Evaluation of the detection of other pathogens in hospitalized patients with COVID-19 at a tertiary hospital in Japan.
    Jpn J Infect Dis. 75(4):419-422,2022.
  23. Tsuzuki S, Hayakawa K, Uemura Y, Shinozaki T, Matsunaga N, Terada M, Suzuki S, Asai Y, Kitajima K, Saito S, Yamada G, Shibata T, Kondo M, Izumi K, Hojo M, Mizoue T, Yokota K, Nakamura-Uchiyama F, Saito F, Sugiura W, Ohmagari N,
    Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 inJapan: A large observational study using the COVID-19 Registry Japan.
    Int J Infect Dis Ther.11(3)1075-1087,2022.
  24. Inada M, Togano T, Terada M, Shiratori K, Tsuzuki S, Takamatsu Y, Saito S, Hangaishi A, Morioka S, Kutsuna S, Maeda K, Mitsuya H, Ohmagari N.
    Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma.
    Transfus Apher Sci. 62(3):103638,2023.
  25. Sugita A, Inagaki FF, Takemura N, Nakamura M, Ito K, Mihara F, Yamamoto K, Morioka S, Kokudo N,
    Liver resection in a patient with persistent positive PCR test for coronavirus disease 2019 (COVID-19): a case report.
    Surg Case Rep. 8(1):200,2022.
  26. Takamatsu Y, Omata K, Shimizu Y, Kinoshita-Iwamoto N, Terada M, Suzuki T, Morioka S, Uemura Y, Ohmagari N, Maeda K, Mitsuya H.
    SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
    Microbiol Spectr. 10(6):e0271622,2022.
  27. Hayakawa K, Morioka S, Asai Y, Tsuzuki S, Yamada G, Suzuki S, Matsunaga N, Ohmagari N.
    Predictors of silent hypoxia in hospitalized patients with COVID-19 in Japan.
    J Infect Chemother. 28(10):1436-8,2022.
  28. Miyazato Y, Tsuzuki S, Morioka S, Terada M, Kutsuna S, Saito S, Shimanishi Y, Takahashi K, Sanada M, Akashi M, Kuge C, Osanai Y, Tanaka K, Suzuki M, Hayakawa K, Ohmagari N.
    Factors associated with development and persistence of post-COVID conditions: A cross-sectional study.
    J Infect Chemother.28(9):1242-8,2022.
  29. Tsuzuki S, Miyazato Y, Terada M, Morioka S, Ohmagari N, Beutels P.
    Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients.
    Health Qual Life Outcomes. 20(1):125,2022.
  30. Matsushita Y, Yokoyama T, Hayakawa K, Matsunaga N, Ohtsu H, Saito S, Saito S, Terada M, Suzuki S, Morioka S, Kutsuna S, Tsuzuki S, Hara H, Kimura A, Ohmagari N.
    Smoking and severe illness in hospitalized COVID-19 patients in Japan.
    Int J Epidemiol. 51(4):1078-87,2022.
  31. Matsushita Y, Yokoyama T, Hayakawa K, Matsunaga N, Ohtsu H, Saito S, Terada M, Suzuki S, Morioka S, Kutsuna S, Tsuzuki S, Hara H, Kimura A, Ohmagari N,
    We should pay more attention to sex differences to predict the risk of severe COVID-19: men have the same risk of worse prognosis as women more than 10 years older.
    J Epidemiol. 33(1) 38-44,2022.
  32. Miyazato Y, Yamamoto K, Nakaya Y, Morioka S, Takeuchi JS, Takamatsu Y, Maeda K, Kimura M, Sugiura W, Mitsuya H, Yano M, Ohmagari N.
    Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
    J Infect Chemother.28(7):991-4,2022.
  33. Okuhama A, Murai Y, Ishikane M, Mezaki K, Isaka E, Matsushiro T, Yamada G, Nomoto H, Yamamoto K, Morioka S, Ohmagari N, Horai T.
    A Case of Vascular Graft Infection Caused by Haemophilus parainfluenzae.
    Open Forum Infect Dis. 9(7):ofac187,2022.
  34. Takamatsu Y, Omata K, Shimizu Y, Kinoshita-Iwamoto N, Terada M, Suzuki T, Morioka S, Uemura Y, Ohmagari N, Maeda K, Mitsuya H.
    SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response
    Microbiol Spectr. 2022 Dec 21;10(6):e0271622.
  35. Tomita N, Saito S, Terada-Hirashima J, Mikami A, Uemura Y, Kutsuna S, Nomoto H, Fujisawa K, Nagashima M, Terada M, Ashida S, Morioka S, Satake M, Hangaishi A, Togano T, Shiratori K, Takamatsu Y, Maeda K, Ohmagari N, Sugiura W, Mitsuya H.
    A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT).
    Life (Basel).12(6)856,2022.
  36. Morioka S, Tsuzuki S, Suzuki M, Terada M, Akashi M, Osanai Y, Kuge C, Sanada M, Tanaka K, Maruki T, Takahashi K, Saito S, Hayakawa K, Teruya K, Hojo M, Ohmagari N.
    Post COVID-19 condition of the Omicron variant of SARS-CoV-2.
    J Infect Chemother. 28(11):1546-1551,2022.
  37. Suzuki T, Morioka S, Kikuchi T, Sato L, Nomoto H, Yamamoto K, Koizumi N, Hayakawa K, Kutsuna S, Ohmagari N.
    Case Report: Leptospirosis by Wild Rat Bite in Winter in Tokyo Metropolitan Area, Japan.
    Am J Trop Med Hyg. 107(1):100-1,2022.
  38. Suzuki T, Morioka S, Nomoto H, Takaya S, Ishikane M, Yanagisawa S, Hayakawa K, Ohmagari N.
    Disseminated Streptococcus anginosus invasive infection with intracranial subdural abscess formation.
    J Infect Chemother. 28(5):696-8,2022.
  39. Matsunaga A, Tsuzuki S, Morioka S, Ohmagari N, Ishizaka Y.
    Long COVID: current status in Japan and knowledge about its molecular background.
    Glob Health Med. 30;4(2):83-93,2022.
  40. Akiyama Y, Morioka S, Asai Y, Sato L, Suzuki S, Saito S, Matsunaga N, Hayakawa K, Ohmagari N.
    Risk factors associated with asymptomatic hypoxemia among COVID-19 patients: a retrospective study using the nationwide Japanese registry, COVIREGI-JP.
    J Infect Public Health.15(3):312-4,2022.
  41. Suzuki T, Asai Y, Ide S, Fukuda S, Tanaka A, Shimanishi Y, Takahashi K, Terada M, Sato L, Sato M, Inada M, Yamada G, Miyazato Y, Akiyama Y, Nomoto H, Nakamoto T, Nakamura K, Togano T, Morioka S, Kinoshita-Iwamoto N, Saito S, Kutsuna S, Ohmagari N.
    Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan.
    J Infect Chemother.28(2):206-10,2022.
  42. Okuhama A, Hotta M, Ishikane M, Kawashima A, Miyazato Y, Terada M, Yamada G, Kanda K, Inada M, Sato L, Sato M, Akiyama Y, Suzuki T, Nakamoto T, Nomoto H, Ide S, Nakamura K, Saito S, Kinoshita N, Yamamoto K, Morioka S, Ujiie M, Hayakawa K, Kustuna S, Shida Y, Tajima T, Teruya K, Funato Y, Yamamoto M, Izumi S, Hojo M, Sugiyama H, Ohmagari N.
    Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease.
    J Infect Chemother.28(2):217-23,2022.
  43. Asai Y, Nomoto H, Hayakawa K, Matsunaga N, Tsuzuki S, Terada M, Ohtsu H, Kitajima K, Suzuki K, Suzuki T, Nakamura K, Morioka S, Saito S, Saito F, Ohmagar N.
    Comorbidities as Risk Factors for Severe Disease in Hospitalized Elderly COVID-19 Patients by Different Age-Groups in Japan.
    Gerontology. 68(9):1027-1037,2022
  44. Morioka S, Tan BH, Kikuchi H, Asai Y, Suzuki T, Ashida S, Kutsuna S, Saito S, Hayakawa K, Tan TT, Kodama E, Ohmagari N.
    Factors Associated With Prolonged Psychological Distress Among Nurses and Physicians Engaged in COVID-19 Patient Care in Singapore and Japan.
    Front Psychiatry. 13:781796,2022.
  45. Nomoto H, Ishikane M, Nakamoto T, Ohta M, Morioka S, Yamamoto K, Kutsuna S, Tezuka S, Kunimatsu J, Ohmagari N.
    Correction: Conjunctivitis, the key clinical characteristic of adult rubella in Japan during two large outbreaks, 2012-2013 and 2018-2019.
    PLoS One. 17(8):e0272880,2022.
  46. Yamamoto K, Ohsiro Y, Suzuki T, Suzuki M, Miura S, Nagashima M, Iwamoto N, Takeuchi JS, Kimura M, Sugiura W, Nebuya S, Kurokawa M, Ohmagari N.
    Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-λ3, CCL17, and calprotectin considering the timing of clinical need for prediction.
    PLoS One.  18(3):e0279897,2022.
  47. Miyazato Y, Yamamoto K, Yamada G, Kubota S, Ishikane M, Sugiyama M, Ueno M, Matsunaga A, Miyoshi-Akiyama T, Ishizaka Y, Ohmagari N.
    Multisystem Inflammatory Syndrome in Adult after First Dose of mRNA Vaccine.
    Emerg Infect Dis.28(4):870-872,2022
  48. Katagiri D*, Asai Y, Ohmagari N, Ishikane M, Hikida S, Iwamoto N, Nagashima M, Suzuki M, Takano H, Takasaki J, Hojo M, Sugiyama H, Tokunaga K, Miyashita Y, Omata M, Ohata K, Bliden KP, Tantry US, Dahlen JR, Sugaya T, Gurbel PA, Noiri E.
    Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases.
    Crit Care Explor. 5(3):e0873.2023.
  49. Koizumi R*, Kusama Y, Asai Y, Tsuzuki S, Aoyagi K, Ishikane M, Muraki Y, Ohmagari N.
    Effects of population age structure on parenteral antimicrobial use estimations.
    Sci Rep. 13(1):840,2023.
  50. Morishita K*, Katase K, Ishikane M, Otomo Y.
    Motivating factors for frontline healthcare workers during the COVID-19 pandemic: A survey in Japan.
    Curr Psychol.1-9,2022.
  51. Yamada G*, Iwamoto N, Ishikane M, Moriya A, Kurokawa M, Mezaki K, Ohmagari N.
    Predictive Performance of Gram Staining of Catheter Tips for Candida Catheter-Related Bloodstream Infections.
    Open Forum Infect Dis. 9(12),2022.
  52. Inada M, Ishikane M*, Gia Binh N, Lan Huong M, Dao XC, Thi Phuong Thuy P, Van Thanh D, Takeshita N, Quoc Anh N, Ohmagari N.
    The Epidemiology of Healthcare-Associated Bloodstream Infection in an Adult Intensive Care Unit: A Retrospective Cohort Study in a Single Tertiary Care Hospital in Hanoi, Vietnam.
    Cureus. 14(11):e31879,2022.
  53. Kanayama S*, Nagata S, Akiyama Y, Miyazato Y, Ishikane M, Inoue M, Ohmagari N, Hara T.
    Cerebral syphilitic Gumma in the modern era: a report of an unusual case and brief review of recent published reports.
    Br J Neurosurg. 1-6,2022.
  54. Tachi Y, Sato L, Ishikane M*, Yamada G, Motohashi A, Ando H, Hayakawa K, Takasaki J, Katsuragawa Y, Ohmagari N.
    A case of prosthetic joint infection caused by Mycobacterium tuberculosis complicated secondary bacterial infection after knee joint replacement surgery.
    J Infect Chemother. 29(3):367-370,2023.
  55. Horinouchi N, Yamaguchi F, Mori H, Ishikane M, Yoshioka T*.
    JImportance of Considering Hospital-Level Variables in Multi-Institutional Studies.
    JClin Infect Dis. 76(8):1523-1524,2023.
  56. Someko H*, Okazaki Y, Tsujimoto Y, Ishikane M, Kubo K, Kakehashi T.
    Diagnostic accuracy of rapid antigen tests in cerebrospinal fluid for pneumococcal meningitis: a systematic review and meta-analysis.
    Clin Microbiol Infect. 29(3):310-319,2023
  57. Kusama Y*, Miyahara M, Ishikane M, Suzuki K, Gu Y, Sasaki J, Ohmagari N.
    Physician practices in the diagnosis and treatment of infectious diseases in home care settings: A questionnaire study.
    Glob Health Med.4(5):268-272,2022.
  58. Nomoto H, Saito H, Ishikane M*, Gu Y, Ohmagari N, Pittet D, Kunishima H, Allegranzi B, Yoshida M.
    First nationwide survey of infection prevention and control among healthcare facilities in Japan: impact of the national regulatory system.
    Antimicrob Resist Infect Control. 11(1):135,2022.
  59. Kuroda N*, Shimizu T, Hirano D, Ishikane M, Kataoka Y.
    Lack of clinical evidence of antiviral therapy for human monkeypox: A scoping review.
    J Infect Chemother. 29(2)228-231,2023.
  60. Nagata N*, Takeuchi T, Masuoka H, Aoki R, Ishikane M, Iwamoto N, Sugiyama M, Suda W, Nakanishi Y, Terada-Hirashima J, Kimura M, Nishijima T, Inooka H, Miyoshi-Akiyama T, Kojima Y, Shimokawa C, Hisaeda H, Zhang F, Yeoh YK, Ng SC, Uemura N, Itoi T, Mizokami M, Kawai T, Sugiyama H, Ohmagari N, Ohno H.
    Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications.
    Gastroenterology.164(2):272-288,2022.
  61. Sato L, Ishikane M*, Okumura N, Iwamoto N, Hayakawa K, Iseki K, Hara H, Ohmagari N.
    A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in Japan, 2022.
    Glob Health Med.;4(4):233-236,2022.
  62. Ghaznavi C*, Ishikane M, Yoneoka D, Tanoue Y, Kawashima T, Eguchi A, Nomura S.
    Effect of the COVID-19 Pandemic and State of Emergency Declarations on the Relative Incidence of Legionellosis and Invasive Pneumococcal Disease in Japan.
    J Infect Chemother. 29(1):90-94,2023
  63. Goto R, Muraki Y*, Inose R, Kusama Y, Ono A, Koizumi R, Ishikane M, Ohmagari N.
    Influence of pharmacists and infection control teams or antimicrobial stewardship teams on the safety and efficacy of vancomycin: A Japanese administrative claims database study.
    PLoS One. 17(9):e0274324,2022.
  64. Goto R*, Kawakami H, Horiuchi Y, Chikada A, Yasuda T, Suzuki T, Miyazato Y, Ishikane M, Kishino Y, Miyazaki H, Igari T, Katano H, Suzuki T, Murayama S, Arai N.
    An Autopsy Report of a Case with Cerebral Infarction Complicated by Coronavirus Disease 2019 Infection.
    Intern Med. 61(22)3439-3444,2022
  65. Saito S, Thao PTN, Ishikane M*, Xuan PT, Kutsuna S, Dai HQ, Ohtsu H, Kimura T, Kiyohara H, Shimada Y, Maruoka Y,
    Thuy PTP, Phu TT, Phuong HK, Tra TT, Duy NLM, Ohara H, Kurosu H, Son NT, Ohmagari N. Physical oral care prevents ventilator-associated pneumonia in Vietnam: A prospective interventional study.
    J Infect Chemother. 28(12):1632-1638,2022
  66. Nomoto H, Ishikane M*, Gu Y, Yamamuro R, Osawa R, Hosokawa N, Sahara T, Nakamura-Uchiyama F, Fukushima K, Sekiya N, Imamura A, Fujikura Y, Kawana A, Nagata K, Tamura K, Kutsuna S, Ohmagari N.
    Nationwide descriptive epidemiological study of patients with COVID-19 evacuated from Wuhan, China, to Japan from January to February 2020.
    Jpn J Infect Dis.76(1):20-26,2023.
  67. Terada-Hirashima J*, Sugiura W, Shimizu Y, Tanaka Y, Uemura Y, Ishikane M,Kazuyama Y, Ikeda M, Wakabayashi K, Ohmagari N, Kimura M.
    Investigation of the use of PCR testing prior to ship boarding to prevent the spread of SARS-CoV-2 from urban areas to less-populated remote islands.
    Glob Health Med.4(3):174-179,2022.
  68. Mizuno K, Inose R, Matsui Y, Takata M, Yamasaki D, Kusama Y, Koizumi R, Ishikane M, Tanabe M, Ohge H, Ohmagari N, Muraki Y.
    Search for Indexes to Evaluate Trends in Antibiotic Use in the Sub-Prefectural Regions Using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
    Antibiotics (Basel). 11(6):763,2022.
  69. Ghaznavi C*, Sakamoto H, Kawashima T, Horiuchi S, Ishikane M, Abe SK, Yoneoka D, Eguchi A, Tanoue Y, Hashizume M, Nomura S.
    Decreased incidence followed by comeback of pediatric infections during the COVID-19 pandemic in Japan.
    World J Pediatr. 18(8):564-567,2022
  70. Ito S, Goto R, Inose R, Kusama Y, Ono A, Koizumi R, Ishikane M, Ohmagari N, Muraki Y*.
    A study of trends and factors associated with therapeutic drug monitoring (TDM) implementation for arbekacin treatment using a large Japanese medical claims database.
    J Infect Chemother. 28(9):1266-1272,2022
  71. Kamegai K, Iwamoto N*, Togano T, Maeda K, Takamatsu Y, Miyazato Y, Ishikane M, Mizokami M, Sugiyama M, Iida S, Miyamoto S, Suzuki T, Ohmagari N.
    A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy.
    Int J Infect Dis. 121:85-88,2022
  72. Moriyama Y*, Ishikane M, Ueno M, Matsunaga A, Ishizaka Y, Arashiro T, Kanno T, Suzuki T, Kimura K.
    A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity.
    J Infect Chemother.28(7):962-964,2022.
  73. Ghaznavi C*, Tanoue Y, Kawashima T, Eguchi A, Yoneoka D, Sakamoto H, Ueda P, Ishikane M, Ando N, Miyazato Y, Nomura S.
    Recent changes in the reporting of STIs in Japan during the COVID-19 pandemic.
    Sex Transm Infect. 99(2):124-127,2023
  74. Tsuchiya K, Maeda K, Matsuda K, Takamatsu Y, Kinoshita N, Kutsuna S, Hayashida T, Gatanaga H, Ohmagari N, Oka S, Mitsuya H.
    Neutralization activity of IgG antibody in COVID 19 convalescent plasma against SARS-CoV-2 variants.
    Sci Rep. 13(1):1263,2023
  75. Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y.
    Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.
    Nat Commun. 14(1):1620,2023
  76. Okumura N, Saito S, Takamatsu Y, Takeuchi JS, Asai Y, Sanada M, Iwamoto N, Maeda K, Mitsuya H, Ohmagari N.
    Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination.
    J Infect Chemother. 28(12):1704-1706,2022.
  77. Horigome A, Yamanaka J, Takasago S, Iwamoto N, Saito T, Shichino H.
    The first case of a child infected with SARS-CoV-2 Omicron variant in Japan, December 2021.
    Jpn J Infect Dis.76(1):69-71,2022.
  78. Ishikane M, Unoki-Kubota H, Moriya A, Kutsuna S, Ando H, Kaburagi Y, Suzuki T, Iwamoto N, Kimura M, Ohmagari N.
    Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 panel, a rapid multiplex PCR method for the diagnosis of COVID-19.
    J Infect Chemother. 28(6):729-734,2022.
  79. Nishida N, Sugiyama M, Kawai Y, Naka I, Iwamoto N,Suzuki T, Suzuki M, Miyazato Y, Suzuki S, Izumi S, Hojo M, Tsuchiura T, Ishikawa M, Ohashi J, Ohmagari N, Tokunaga K, Mizokami M.
    Genetic association of IL17 and the importance of ABO blood group antigens in saliva to COVID-19.
    Sci Rep.12(1):3854,2022.
  80. Takahashi K, Ishikane M, Ujiie M, Iwamoto N,  Okumura N, Sato T, Nagashima M, Moriya A, Suzuki M, Hojo M, Kanno T, Saito S, Miyamoto S, Ainai A, Tobiume M, Arashiro T, Fujimoto T, Saito T, Yamato M, Suzuki T, Ohmagari N.
    Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees.
    Emerg Infect Dis. 28(5):998-1001,2022.
  81. Shoji K, Akiyama T, Tsuzuki S, Matsunaga N, Asai Y, Suzuki S, Iwamoto N, Funaki T, Ohmagari N. 
    Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan.
    J Infect Chemother. 28(4):591-594,2022.
  82. Takahata H, Onishi K, Nomoto H, et al.
    Surveillance and risk assessment of health screening for vaccine-preventable diseases among international students in Japan: A cross-sectional study in 2020.
    Hum Vaccin Immunother. 18(6):2136914,2022.
  83. Nomoto H, Asai Y, Hayakawa K, Matsunaga N, Kutsuna S, Kodama EN, Ohmagari N.
    Impact of the COVID-19 pandemic on racial and ethnic minorities in Japan.
    Epidemiol Infect. 150:e202,2022.
  84. Nomoto H, Yamamoto K, Isaka E, et al. 
    Potential usage of anterior nasal sampling in clinical practice with three rapid antigen tests for SARS-CoV-2.
    J Infect Chemother. 29(1):15-19,2023.
  85. Nomoto H, Hayakawa K, Ohmagari N.
    Impact of prioritized vaccinations for the elderly on the COVID-19 pandemic in Japan.
    Glob Health Med. 4(2):129-132,2022.
  86. Shinozawa S, Moriyama Y.
    Three SARS-CoV-2 PCR-negative cases of COVID-19 diagnosed using isothermal amplification methods.
    J Infect Chemother.28（7）：1005-1007,2022.
  87. Suzuki M, Hayakawa K*, Asai Y, Terada M, Kitajima K, Tsuzuki S, Moriya A, Moriya K, Uchiyama-Nakamura F, Ohmagari N.
    Characteristics of hospitalized COVID-19 patients with other respiratory pathogens identified by rapid diagnostic test.
    J Infect Chemother. S1341-321X(23)00042-9,2023.
  88. Inada M, Saito S*, Tsuzuki S, Okumura N, Sato L, Kamegai K, Sanada M, Komatsubara M, Shimojima M, Ebihara H, Kasuya F, Nagashima M, Sadamasu K, Yamamoto K, Ujiie M, Morioka S, Ohmagari N. 
    Treatment with tecovirimat of the first two cases of monkeypox in Japan.
    J Infect Chemother. S1341-321X(23)00019-3,2023.
  89. Morioka S*, Tsuzuki S, Maruki T, Terada M, Miyazato Y, Kutsuna S, Saito S, Shimanishi Y, Takahashi K, Sanada M, Ashida S, Akashi M, Kuge C, Osanai Y, Tanaka K, Suzuki M, Hayakawa K, Ohmagari N. 
    Epidemiology of post-COVID conditions beyond 1 year: A cross-sectional study.
    Public Health. 216:39-44,2023.
  90. Asai Y*, Tsuzuki S, Matsunaga N, Ohmagari N.
    Regional trends in the use of steroids and favipiravir for COVID-19 treatment.
    Journal of Infection and Public Health. 16(2)206-213,2022.
  91. Tsuzuki S*, Asai Y, Ibuka Y, Nakaya T, Ohmagari N, Hens N, Beutels P.
    Social contact patterns in Japan in the COVID-19 pandemic during and after the Tokyo Olympic Games.
    J Glob Health. 12:05047,2022.
  92. Tsuzuki S*, Akiyama T, Matsunaga N, Ohmagari N.
    Association between physical activity status and severity of COVID-19 in older adults.
    Epidemiol Infect. 150:e189,2022.
  93. Hayakawa K*, Asai Y, Matsunaga N, Tsuzuki S, Terada M, Suzuki S, Kitajima K, Saito S, Ohmagari N.. 
    Evaluation of the representativeness of data in the COVID-19 Registry Japan during the first six waves of the epidemic.
    Glob Health Med. 4(4):204-209,2022.
  94. Endo A, Asai Y, Tajima T, Endo M, Akiyama T, Matsunaga N, Ishioka H, Tsuzuki S*, Ohmagari N. 
    Temporal trends in microbial detection during the COVID-19 pandemic: analysis of the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) database.
    J Infect Chemother. 29(1):98-101,2023.
  95. Shoji K*, Tsuzuki S, Akiyama T, Matsunaga N, Asai Y, Suzuki S, Iwamoto N, Funaki T, Yamada M, Ozawa N, Yamaguchi K, Miyairi I, Ohmagari N. 
    Comparison of clinical characteristics of COVID-19 in pregnant women between the Delta and Omicron variants of concern predominant periods.
    J Infect Chemother. 29(1):33-38.2023
  96. Tsuzuki Y*, Hirata T, Tsuzuki S, Wada S, Tamakoshi A. 
    Does the experience of the first assistant affect organ injuries in laparoscopic hysterectomy for benign diseases?
    Arch Gynecol Obstet.307(2):453-458,2023.
  97. Uchikoba S, Yamada G, Tsuzuki S*. 
    Methodological concerns regarding a retrospective study with real-world data on Paxlovid® in Israel.
    Clin Infect Dis. 75(12):2278-2279,2022.
  98. Shoji K*, Akiyama T, Tsuzuki S, Matsunaga N, Asai Y, Suzuki S, Iwamoto N, Funaki T, Ohmagari N. 
    Clinical characteristics of COVID-19 in hospitalized children during the Omicron variant predominant period.
    J Infect Chemother. 28(11):1531-1535,2022.
  99. Matsunaga N, Kamata K, Asai Y, Tsuzuki S*, Sakamoto Y, Ijichi S, Akiyama T, Yu J, Yamada G, Terada M, Suzuki S, Suzuki K, Saito S, Hayakawa K, Ohmagari N. 
    Predictive Model of Risk Factors of High Flow Nasal Cannula Using Machine Learning in COVID-19.
    Infect Dis Model. 7(3):526-534,2022.
  100. Terada M, Tsuzuki S*, Asai Y, Saito S, Ohmagari N. 
    Considerations and concerns regarding the readiness to remove face coverings.
    J Glob Health. 12:03036,2022.
  101. Okumura N, Tsuzuki S, Saito S*, Saito T, Takasago S, Hojo M, Iwamoto N, Ohmagari N. 
    The first eleven cases of SARS-CoV-2 Omicron variant infection in Japan: A focus on viral dynamics.
    Glob Health Med. 4(2):133-136,2022.
  102. Yoshihara F, Ohtsu H, Nakai M*, Tsuzuki S, Hayakawa K, Terada M, Matsunaga N, Yasuda S, Ogawa H, Ohmagari N. 
    Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan.
    J Cardiol. 80(4):292-297,2022.
  103. Ono A, Koizumi R, Tsuzuki S*, Asai Y, Ishikane M, Kusama Y, Ohmagari N. 
    Antimicrobial Use Fell Substantially in Japan in 2020-The COVID-19 Pandemic May Have Played a Role.
    Int J Infect Dis. 119:13-17,2022.
  104. Tsuzuki S*, Hayakawa K, Yohei Doi, Shinozaki T, Uemura Y, Matsunaga N, Terada M, Suzuki S, Asai Y, Kitajima K, Saito S, Yamada G, Shibata T, Kondo M, Izumi K, Hojo M, Mizoue T, Yokota K, Nakamura-Uchiyama F, Saito F, Sugiura W, Ohmagari N. 
    Effectiveness of favipiravir on nonsevere, early-stage COVID-19 in Japan: a large observational study using the COVID-19 Registry Japan.
     Infect Dis Ther.  11(3): 1075-1087,2022. 
Presentations at International Conferences and Forums
  1. Sugita A, Ishikane M*, Iwamoto N, Sugiyama S, Teruya K, Hojo M, Mizogami M, Ohmagari N. 
    Retrospective study evaluating the cytokine dynamics in COVID-19 patients who were treated with casirivimab/imdevimab.
     IDWeeK 2022. (Washington DC, USA, Oct 2022)
  2. Ono A, Koizumi R, Tsuzuki S, Asai Y, Kusama Y, Ishikane M, Ohmagari N. 
    Antimicrobials use estimation in 2020 from the SARIMA model in Japan.
    The 32th European Congress of Clinical　Microbiology and Infectious Diseases.(Lisbon, Portugal, Apr 2022)
  3. Koizumi R, Kusama Y, Asai Y, Tsuzuki S, Ishikane M, Muraki Y, Ohmagari N. 
    Antimicrobial use monitoring in countries experiencing population ageing needs incorporating changes in population structure.
    The 32th European Congress of Clinical　Microbiology and Infectious Diseases.(Lisbon, Portugal, Apr 2022)
  4. Koizumi R *, Tanaka C, Endo M, Fujitomo Y, Tsuzuki S, Asai Y, Ono A, Muraki Y, Kitahara T, Ohmagari N. 
    Cross-sectional survey on education of clinical infectious diseases and antimicrobial resistance in pharmaceutical department in Japanese universities.
    IDWEEK 2022,(Washington DC,　USA, Oct 2022)
  5. Tsuzuki S*, Asai Y, Matsunaga N, Ishioka H, Akiyama T, Ohmagari N. 
    Impact of regional heterogeneity on the severity of COVID-19.
    ECCMID2022.( Lisbon, Portugal. Apr 2022)
  6. Tsuzuki S*, Miyazato Y, Terada M, Morioka S, Ohmagari N. 
    Beutels P. Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients.
    ECCMID2022. (Lisbon, Portugal. Apr 2022.)

Fiscal Year

SITE MAP ＋